Regen Biopharma Stock Performance
| RGBPP Stock | USD 0.10 0 2.15% |
Regen BioPharma holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 7.57, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Regen BioPharma will likely underperform. Use Regen BioPharma sortino ratio and the relationship between the downside variance and market facilitation index , to analyze future returns on Regen BioPharma.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Regen BioPharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile basic indicators, Regen BioPharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 727.2 K | |
| Total Cashflows From Investing Activities | 25 K |
Regen |
Regen BioPharma Relative Risk vs. Return Landscape
If you would invest 21.00 in Regen BioPharma on August 30, 2024 and sell it today you would lose (11.00) from holding Regen BioPharma or give up 52.38% of portfolio value over 90 days. Regen BioPharma is currently producing 6.2032% returns and takes up 47.649% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Regen, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Regen BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regen BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Regen BioPharma, and traders can use it to determine the average amount a Regen BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1302
| Best Portfolio | Best Equity | RGBPP | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 47.65 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Regen BioPharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regen BioPharma by adding it to a well-diversified portfolio.
Regen BioPharma Fundamentals Growth
Regen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Regen BioPharma, and Regen BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regen Pink Sheet performance.
| Return On Asset | -0.76 | |||
| Profit Margin | 6.09 % | |||
| Operating Margin | (2.96) % | |||
| Current Valuation | 304.65 M | |||
| Shares Outstanding | 158.73 M | |||
| Price To Earning | (0.88) X | |||
| Price To Sales | 4.60 X | |||
| Revenue | 235.52 K | |||
| EBITDA | 2.65 M | |||
| Cash And Equivalents | 110.99 K | |||
| Total Debt | 1.58 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (606.92 K) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 559 K | |||
About Regen BioPharma Performance
Assessing Regen BioPharma's fundamental ratios provides investors with valuable insights into Regen BioPharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Regen BioPharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California. Regen Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Regen BioPharma performance evaluation
Checking the ongoing alerts about Regen BioPharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Regen BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regen BioPharma is way too risky over 90 days horizon | |
| Regen BioPharma has some characteristics of a very speculative penny stock | |
| Regen BioPharma appears to be risky and price may revert if volatility continues | |
| Regen BioPharma has accumulated 1.58 M in total debt. Regen BioPharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Regen BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Regen BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regen BioPharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regen to invest in growth at high rates of return. When we think about Regen BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Regen BioPharma has accumulated about 110.99 K in cash with (606.92 K) of positive cash flow from operations. | |
| Roughly 55.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Regen BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regen BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Regen BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regen BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regen BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regen BioPharma's pink sheet. These opinions can provide insight into Regen BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.